Tumor Biology

, Volume 34, Issue 1, pp 39–45 | Cite as

Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma

Research Article


This study aims to evaluate the impact of pretreatment thrombocytosis on survival in patients with nasopharyngeal carcinoma (NPC). The data of 1,582 patients with NPC, who underwent definitive treatment between 2003 and 2004, were retrospectively reviewed. The correlation between the clinicopathological variables and the platelet count was analyzed. The prognostic significance of thrombocytosis, together with various clinicopathological factors, was evaluated by univariate and multivariate analyses. Platelet count showed significant correlation with gender, clinical stage, and T stage in univariate analysis. There was poorer 5-year disease-specific survival (DSS) in the patients with thrombocytosis than in those without thrombocytosis (70 vs. 78 %; p = 0.001) and poorer metastases-free survival (MFS) (81 vs. 88 %; p = 0.006). Univariate and multivariate analyses showed that thrombocytosis was an independent prognostic factor for MFS and DSS. Thrombocytosis is a useful predictor of metastasis and poor prognosis in patients with NPC.


Thrombocytosis Platelet count Nasopharyngeal carcinoma Survival Metastasis 


Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107.PubMedCrossRefGoogle Scholar
  2. 2.
    Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer. 2011;47(5):656–66. doi: 10.1016/j.ejca.2010.10.026.PubMedCrossRefGoogle Scholar
  3. 3.
    Kim YJ, Go H, Wu HG, Jeon YK, Park SW, Lee SH. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck. 2011;33(10):1458–66. doi: 10.1002/hed.21611.PubMedCrossRefGoogle Scholar
  4. 4.
    Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, et al. Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res. 2007;13(2 Pt 1):508–14. doi: 10.1158/1078-0432.CCR-06-1512.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee M, Kim SW, Nam EJ, Yim GW, Kim S, Kim YT. The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2011;122(2):238–41. doi: 10.1016/j.ygyno.2011.04.012.PubMedCrossRefGoogle Scholar
  6. 6.
    Seda CJ, Salas AS, Sanchez CG, Blasco JM, Garcia IO, Sanchez JM, et al. Thrombocytosis and hematocrit as prognostic factors in renal carcinoma. Arch Esp Urol. 2011;64(9):883–90.PubMedGoogle Scholar
  7. 7.
    Cho DS, Kim SJ, Lee SH, Ahn HS, Kim YS, Kim SI. Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. Korean J Urol. 2011;52(2):104–9. doi: 10.4111/kju.2011.52.2.104.PubMedCrossRefGoogle Scholar
  8. 8.
    Lin MS, Huang JX, Zhu J, Shen HZ. Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology. 2012;59(118):1687–90. doi: 10.5754/hge12277.PubMedGoogle Scholar
  9. 9.
    Hwang SG, Kim KM, Cheong JH, Kim HI, An JY, Hyung WJ, et al. Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol. 2012;38(7):562–7. doi: 10.1016/j.ejso.2012.04.009.PubMedCrossRefGoogle Scholar
  10. 10.
    Gorelick C, Andikyan V, Mack M, Lee YC, Abulafia O. Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population. Int J Gynecol Cancer. 2009;19(8):1384–9. doi: 10.1111/IGC.0b013e3181a47d47.PubMedCrossRefGoogle Scholar
  11. 11.
    Lu CC, Chang KW, Chou FC, Cheng CY, Liu CJ. Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol. 2007;43(3):283–8. doi: 10.1016/j.oraloncology.2006.03.010.PubMedCrossRefGoogle Scholar
  12. 12.
    Greene F. AJCC cancer staging handbook: from the AJCC cancer staging manual. New York: Springer; 2002.Google Scholar
  13. 13.
    Gonzalez Barcala FJ, Garcia Prim JM, Moldes Rodriguez M, Alvarez Fernandez J, Rey Rey MJ, Pose Reino A, et al. Platelet count: association with prognosis in lung cancer. Med Oncol. 2010;27(2):357–62. doi: 10.1007/s12032-009-9217-9.PubMedCrossRefGoogle Scholar
  14. 14.
    Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer. 2012;130(12):2747–60. doi: 10.1002/ijc.27441.PubMedCrossRefGoogle Scholar
  15. 15.
    Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008;8(8):1247–55. doi: 10.1586/14737140.8.8.1247.PubMedCrossRefGoogle Scholar
  16. 16.
    Gerotziafas GT, Papageorgiou C, Hatmi M, Samama MM, Elalamy I. Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb. 2008;36(3–4):204–11. doi: 10.1159/000175158.PubMedGoogle Scholar
  17. 17.
    Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004;30(1):95–108. doi: 10.1055/s-2004-822974.PubMedCrossRefGoogle Scholar
  18. 18.
    Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610–8. doi: 10.1056/NEJMoa1110352.PubMedCrossRefGoogle Scholar
  19. 19.
    Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K. Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int. 2007;79(2):111–6. doi: 10.1159/000106322.PubMedCrossRefGoogle Scholar
  20. 20.
    Crasta JA, Premlatha TS, Krishnan SM, Vallikad E, Rameshkumar K. Significance of preoperative thrombocytosis in epithelial ovarian cancer. Indian J Pathol Microbiol. 2010;53(1):54–6. doi: 10.4103/0377-4929.59184.PubMedCrossRefGoogle Scholar
  21. 21.
    Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J. Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg. 2012;36(1):192–200. doi: 10.1007/s00268-011-1329-7.PubMedCrossRefGoogle Scholar
  22. 22.
    Choe KS, Correa D, Jani AB, Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer. 2010;116(7):1820–6. doi: 10.1002/cncr.24890.PubMedCrossRefGoogle Scholar
  23. 23.
    Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110(5):1149–61. doi: 10.1002/cncr.22892.PubMedCrossRefGoogle Scholar
  24. 24.
    Phillips PG, Yalcin M, Cui H, Abdel-Nabi H, Sajjad M, Bernacki R, et al. Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res. 2011;31(2):411–9.PubMedGoogle Scholar
  25. 25.
    van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol. 2011;29(15):2071–6. doi: 10.1200/JCO.2010.31.9293.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  1. 1.Department of Radiation Oncology, Cancer CenterSun Yat-Sen UniversityGuangzhouPeople’s Republic of China
  2. 2.Department of Radiation OncologyAnhui Provincial HospitalHefeiPeople’s Republic of China

Personalised recommendations